Understanding the Effect of Propolis and Its Derivatives Against Candida Biofilm: New Approaches in the Search for Alternative Therapies.

Propolis is a bee product with a complex chemical composition that exhibits remarkable antifungal activity against C. albicans and can inhibit resistant biofilms thanks to its content of compounds such as flavonoids and phenolic acids. Its efficacy varies depending on its geographic origin: European propolis inhibits the initial formation of biofilms, while Brazilian propolis is superior at inhibiting mature biofilms. This product also possesses fungicidal and fungistatic properties comparable in efficacy to conventional drugs, such as nystatin, fluconazole, and chlorhexidine. The use of nanotechnology, such as nanoparticles or nanorods, has overcome the low solubility of propolis compounds, improving their bioavailability and reducing cell adhesion and hyphal formation. Moreover, the integration of propolis into dental materials demonstrate its versatility for preventing recurrent infections. The study of isolated compounds such as pinocembrin, galangin, and chrysin has facilitated the identification of specific mechanisms of action, and the application of molecules such as guttiferone E in photodynamic therapies and the discovery of quorum-sensing inhibitors, such as kaempferol, using in silico models have opened new avenues for blocking yeast communication and virulence. These findings position propolis as a multifaceted and promising therapeutic alternative, although there is a need to optimize formulations to ensure clinical safety and biocompatibility. In this review, we analyze research published around the world over the last 15 years on the effects of propolis against C. albicans biofilms.